Respiratory Viruses: Often More Than a Sniffle
Respiratory viruses like the common cold, flu, COVID-19, and RSV are everywhere during the colder months. Though they can…
more.Rally for Access
Published March 24, 2022
In June 2021, the Food and Drug Administration (FDA) approved a new treatment for Alzheimer’s disease–the first new therapy Alzheimer’s therapy in almost 20 years. But in January 2022, the Centers for Medicare and Medicaid Services (CMS) announced it has no plans to cover the treatment for most seniors. Even worse, CMS’ decision will extend to future FDA approved Alzheimer’s treatments in this class of drugs. So on March 15, 2022, patients and advocates gathered to make sure their voices were heard. This video shares highlights from the rally.
Related Alzheimer’s Disease Videos
Medical Advice — Not Policy — Should Drive Care for Patients with Alzheimer’s and NPS
Alzheimer’s Disease and related Dementias not only rob people of their memories, but it can change their personalities and…
more.
Caring for a Loved One With Alzheimer’s Disease and Neuropsychiatric Symptoms: Anxiety & Depression
Carolyn Clevenger is a geriatric nurse practitioner at Emory University, where she leads the Integrative Memory Care Clinic. Carolyn cares…
more.Related Initiative
Alzheimer’s Disease Policy Task Force
The Alzheimer’s Disease Policy Task Force is an ad hoc coalition of patient, family caregiver, and professional organizations, working collectively to organize and educate the Alzheimer’s disease community and decisionmakers on the Food & Drug Administration’s (FDA) Accelerated Approval pathway, and the Centers for Medicare & Medicaid Services’ (CMS) coverage determination processes for amyloid-targeted monoclonal antibody therapies for the treatment of Alzheimer’s disease.